Atlas Bio raises $12.5M to simulate clinical trials with AI
Swiss startup Atlas Bio secures $12.5M to tackle drug development’s 70% failure rate and move beyond animal testing
AI Overview
Swiss tech-bio startup Atlas Bio launched from stealth with $12.5M total funding.
Why it matters
Atlas Bio's seed round shows investors backing in silico clinical trials as a replacement for Phase II and animal studies, with one client already skipping animal testing.